ArticleNeuroradiology2019
Dynamic susceptibility contrast and diffusion MR imaging identify oligodendroglioma as defined by the 2016 WHO classification for brain tumors: histogram analysis approach.
Article in Neuroradiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 39 citations in OpenAlex.
- Contrast-enhancement in supratentorial low-grade gliomas: a classic prognostic factor in the molecular age.Journal of neuro-oncology · 2019Trial
- The diagnostic value of cortical high-flow sign combined with cystathionine onNeuroradiology · 2026Article
- Longitudinal Cerebral Structural, Microstructural, and Functional Alterations After Brain Tumor Surgery for Early Detection of Recurrent Tumors.Biomedicines · 2025Article
- Advanced MRI, Radiomics and Radiogenomics in Unravelling Incidental Glioma Grading and Genetic Status: Where Are We?Medicina (Kaunas, Lithuania) · 2025Review
- IDH mutant high-grade gliomas.Frontiers in molecular neuroscience · 2025Review
- Predicting IDH and 1p/19q molecular status of gliomas with multi-b values DWI.Frontiers in oncology · 2025Article
- Differentiating IDH-mutant astrocytomas and 1p19q-codeleted oligodendrogliomas using DSC-PWI: high performance through cerebral blood volume and percentage of signal recovery percentiles.European radiology · 2024Article
- The cortical high-flow sign of oligodendroglioma, IDH-mutant and 1p/19q-codeleted: comparison between arterial spin labeling and dynamic susceptibility contrast methods.Neuroradiology · 2024Article
- Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification.European radiology · 2024Article
- Distributed parameter model of dynamic contrast-enhanced MRI in the identification of IDH mutation, 1p19q codeletion, and tumor cell proliferation in glioma patients.Frontiers in oncology · 2024Article
- Cortical high-flow sign on arterial spin labeling: a novel biomarker for IDH-mutation and 1p/19q-codeletion status in diffuse gliomas without intense contrast enhancement.Neuroradiology · 2023Article
- Feasibility of evaluating the histologic and genetic subtypes of WHO grade II-IV gliomas by diffusion-weighted imaging.BMC neuroscience · 2022Article
- 2021 WHO classification of tumours of the central nervous system: a review for the neuroradiologist.Neuroradiology · 2022Review
- Review
- Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System.Laboratory investigation; a journal of technical methods and pathology · 2022Review
- Determining chromosomal arms 1p/19q co-deletion status in low graded glioma by cross correlation-periodogram pattern analysis.Scientific reports · 2021Article
- StaticEuropean radiology · 2021Article
- Voxelwise and Patientwise Correlation ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Dynamic Susceptibility Perfusion Imaging for Differentiating Progressive Disease from Pseudoprogression in Diffuse Glioma Molecular Subtypes.Journal of clinical medicine · 2021Article
- Advancements in Neuroimaging to Unravel Biological and Molecular Features of Brain Tumors.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
purposeAccording to the revised World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS) of 2016, oligodendrogliomas are now defined primarily by a specific molecular signature (presence of IDH mutation and 1p19q codeletion). The purpose of our study was to assess the value of dynamic susceptibility contrast MR imaging (DSC-MRI) and diffusion-weighted imaging (DWI) to characterize oligodendrogliomas and to distinguish them from astrocytomas.
methodsSeventy-one adult patients with untreated WHO grade II and grade III diffuse infiltrating gliomas and known 1p/19q codeletion status were retrospectively identified and analyzed using relative cerebral blood volume (rCBV) and apparent diffusion coefficient (ADC) maps based on whole-tumor volume histograms. The Mann-Whitney U test and logistic regression were used to assess the ability of rCBV and ADC to differentiate between oligodendrogliomas and astrocytomas both independently, but also related to the WHO grade. Prediction performance was evaluated in leave-one-out cross-validation (LOOCV).
resultsOligodendrogliomas showed significantly higher microvascularity (higher rCBV
conclusionHistogram-derived rCBV and ADC parameter may be used as biomarkers for identification of oligodendrogliomas and may help characterize diffuse gliomas based upon their genetic characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.